Security key
48301N104
Kairos Pharma, LTD. - Common Stock, par value $0.001 per share (KAPA)
CUSIP: 48301N104
Q2 2025 13F Holders as of 30 Jun 2025
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 174,435
- Total 13F value
- $123,288
- Share change
- -1,358,525
- SEC-reported price per share
- $0.71
- Number of holders
- 9
- Value change
- -$1,296,527
- Number of buys
- 8
- Number of sells
- 3
- Shares outstanding
- 17,734,228
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2025
Institutions
9
Top holders
9
KAPA full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
Previous quarter: Q1 2025
Kairos Pharma, LTD. SEC filings
Kairos Pharma, LTD. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 48301N104
Recent filing periods:
Ownership snapshot
Top reported holders of KAPA - Kairos Pharma, LTD. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ARMISTICE CAPITAL, LLC
Disclosed value leader
ARMISTICE CAPITAL, LLC
Comparable rows
8/8
Latest evidence
31 Mar 2025
13F
13D/G
Lead comparable stake: 5%
13D/G row: ARMISTICE CAPITAL, LLC
Showing 1-6 of 8 holder rows.
Quick read
ARMISTICE CAPITAL, LLC leads the comparable SEC ownership view at 5%.
8 of 8 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ARMISTICE CAPITAL, LLC's linked filing trail.
Comparable ownership
Top 5
ARMISTICE CAPITAL, LLC
5%
Scientech Research LLC
0.27%
Aptus Capital Advisors, LLC
0.25%
SevenBridge Financial Group, LLC
0.25%
GEODE CAPITAL MANAGEMENT, LLC
0.12%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 8 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
13F
13D/G
Company
|
5%
from 13D/G
|
$1,314,425
1,404,000 shares
|
— | 31 Mar 2025 |
| Scientech Research LLC |
13F
Company
|
0.27%
|
$45,123
48,198 shares
|
— | 31 Mar 2025 |
| Aptus Capital Advisors, LLC |
13F
Company
|
0.25%
|
$41,461
44,286 shares
|
— | 31 Mar 2025 |
| SevenBridge Financial Group, LLC |
13F
Company
|
0.25%
|
$28,343
44,286 shares
|
— | 31 Mar 2025 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
0.12%
|
$19,129
20,433 shares
|
— | 31 Mar 2025 |
| CITADEL ADVISORS LLC |
13F
Company
|
0.07%
|
$12,386
13,230 shares
|
— | 31 Mar 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
9
Shares
174,435
Rows available
9
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
8
Q2 2025 holders
9
Holder diff
1
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q2 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend